Pharmaceutisch Weekblad

, Volume 13, Issue 4, pp 182–188 | Cite as

Clinimetrics and epilepsy care

  • D. J. P. Wijsman
  • Y. A. Hekster
  • A. Keyser
  • W. O. Renier
  • H. Meinardi


In order to study the practicability of rating scales in the regular care of people with epilepsy, indices have been developed and tested on their validity. These indices consist of the Index of Seizures, representing seizure activity, and the Composite Index of Impairment concerning the severity of impairment caused by the seizure type and frequency and the side-effects of anti-epileptic drug treatment. The indices have been applied in a retrospective quantitative evaluation of anti-epileptic drug therapy. The medical records of 250 randomly selected patients registered at an adult out-patient clinic have been reviewed. Their seizures have been classified as generalized tonic-clonic, simple partial and/or complex partial. The distribution of this population according to these indices has been studied, which leads us to the following conclusions:
  • the global indices are valid for clinical application;

  • in 18.6% of the patients studied there was severe impairment and unacceptable seizure control;

  • combined types of seizure are difficult to control;

  • no significant difference is demonstrated between monotherapy and polytherapy regarding the amount of neurotoxicity.

The indices can be determined rapidly and therefore may become valuable aids for the physician in an out-patient clinic to support a decision whether or not to revise current anti-epileptic drug therapy.


Anticonvulsants Classification Clinimetrics Drug therapy Drug therapy, combination Epidemiology Epilepsy Rating scales Seizures Side-effects 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Beghi E, Di Mascio R, Tognoni G. Drug treatment of epilepsy. Outlines, criticism and perspectives. Drugs 1986;31:249–65.PubMedGoogle Scholar
  2. 2.
    Feinstein AR. Clinimetrics. New Haven: Yale University Press, 1987.Google Scholar
  3. 3.
    Cramer JA, Mattson RH, Smith DB, et al. A method of quantification for the evaluation of antiepileptic drug therapy. Neurology 1983;33(Suppl 1):26–37.PubMedGoogle Scholar
  4. 4.
    Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic clonic seizures. N Engl J Med 1985;313:145–51.PubMedGoogle Scholar
  5. 5.
    Gowers WR. Epilepsy and other chronic convulsive diseases. London: Churchill, 1881.Google Scholar
  6. 6.
    Reynolds EH. Iatrogenic disorders in epilepsy. In: Williams D, ed. Modern trends in neurology; vol. 5. London: Butterworth, 1970:271–86.Google Scholar
  7. 7.
    Rwiza HT, Keyser A, Hekster YA, et al. Retrospective analysis of drug treatment in epileptic patients. Pharm Weekbl [Sci] 1989;11(2):50–5.Google Scholar
  8. 8.
    Anonymous. WHO-International Classification of impairments, disabilities and handicaps. Geneva: World Health Organization, 1980.Google Scholar
  9. 9.
    Trimble MR. Chronic epilepsy. Its prognosis and management. Chichester: John Wiley & Sons, 1989.Google Scholar
  10. 10.
    Meldrum BS. Pathophysiology of chronic epilepsy. In: Trimble MR, ed. Chronic epilepsy. Its prognoses and management. Chichester: John Wiley & Sons, 1989:1–11.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1991

Authors and Affiliations

  • D. J. P. Wijsman
    • 1
  • Y. A. Hekster
    • 2
  • A. Keyser
    • 1
  • W. O. Renier
    • 1
  • H. Meinardi
    • 1
  1. 1.Institute of NeurologyUniversity Hospital NijmegenHB NijmegenThe Netherlands
  2. 2.Department of Clinical PharmacyUniversity Hospital NijmegenThe Netherlands

Personalised recommendations